A Phase 4 interventional study of A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE® and Sodium hyaluronate in Dry Eye Syndromes, sponsored by Allergan. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-19.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing Hyaluronic Acid in Dry Eye Syndromes — 3 open to participants now, 3 under way, none of them phase 3. Hyaluronic Acid · Dry Eye Syndromes.
Among the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes, this one is the 13th largest by enrollment, is one of 2 that started in 2007, is one of 5 in phase 4, and was the 2nd registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →3 of the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:
Jin Yang · Sites in China
Beijing Tongren Hospital · Sites in China
Ages 18–65
He Eye Hospital
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 2 · Phase 4 5
First in 2006; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 88 across the 18 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
48 studies in Dry Eye Syndromes by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 47 finished, 40 (85%) have results posted.
Among the 48 studies in Dry Eye Syndromes by AbbVie, this one is the 28th largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2007, is one of 9 in phase 4, and was the 7th registered.
AbbVie’s Dry Eye Syndromes studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 48 in Dry Eye Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the performance and acceptance of Optive versus Hylocomod eyedrops, when administered for one month to patients with mild to moderate dry eye symptoms, with and without contact lenses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Optive Eyedrops
Drug: A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®
Hylocomod Eyedrops
Drug: Sodium hyaluronate
Eyedrops as required, but at least 3 times per day
Also known as: Optive™ Eyedrops
Eyedrops as required, but at least 3 times per day
Also known as: Hylocomod
Conjunctival Staining by Lissamine Green
Percentage of cases of limbal staining by lissamine green at each point on a five point scale (0 = None, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe)
Time frame: week 1, month 1
Corneal Staining by Fluorescein
Percentage of cases of limbal staining by sodium fluorescein at each point on a five point scale (0 = None, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe)
Time frame: week 1, month 1
Conjunctival Hyperaemia
Percentage of conjunctival response reported in terms of limbal hyperaemia for the worst responses over the area at each point on a five point scale (0=clear/white conjunctiva, 1=slight redness, 2=Mild redness, 3=Moderate redness, 4=Severe redness)
Time frame: week 1, month 1
Ocular Comfort and Ocular Symptoms on Visual Analogue Scale
Mean comfort judged on a 100 point visual analogue scale (0=Very Poor, 100=Excellent)
Time frame: week 1, month 1
Daily Eyedrop Usage
Average daily eyedrop use
Time frame: Month 1
Lipid Layer Pattern Assessment
Lipid layer thickness as determined by lipid layer mixing pattern. A high mixing pattern = thick lipid layer.
Time frame: Week 1, month 1
| Milestone | Carboxymethylcellulose and Glycerin | Sodium Hyaluronate |
|---|---|---|
| Started | 22 | 28 |
| Completed | 21 | 26 |
| Not completed | 1 | 2 |
Percentage of cases of limbal staining by lissamine green at each point on a five point scale (0 = None, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe)
| Percentage of Participants | Carboxymethylcellulose and Glycerin | Sodium Hyaluronate |
|---|---|---|
| Week 1 - None | 50.0 | 53.8 |
| Week 1 - Trace | 17.5 | 15.4 |
| Week 1 - Mild | 17.5 | 25.0 |
| Week 1 - Moderate | 15.0 | 5.8 |
| Week 1 - Severe | 0.0 | 0.0 |
| Month 1 - None | 78.6 | 50.0 |
| Month 1 - Trace | 11.9 | 17.3 |
| Month 1 - Mild | 9.5 | 25.0 |
| Month 1 - Moderate | 0.0 | 7.7 |
| Month 1 - Severe | 0.0 | 0.0 |
Percentage of cases of limbal staining by sodium fluorescein at each point on a five point scale (0 = None, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe)
| Percentage of Participants | Carboxymethylcellulose and Glycerin | Sodium Hyaluronate |
|---|---|---|
| Week 1 - None | 45.0 | 57.7 |
| Week 1 - Trace | 25.0 | 15.4 |
| Week 1 - Mild | 15.0 | 25.0 |
| Week 1 - Moderate | 15.0 | 1.9 |
| Week 1 - Severe | 0.0 | 0.0 |
| Month 1 - None | 73.8 | 51.9 |
| Month 1 - Trace | 21.4 | 15.4 |
| Month 1 - Mild | 4.8 | 26.9 |
| Month 1 - Moderate | 0.0 | 5.8 |
| Month 1 - Severe | 0.0 | 0.0 |
Percentage of conjunctival response reported in terms of limbal hyperaemia for the worst responses over the area at each point on a five point scale (0=clear/white conjunctiva, 1=slight redness, 2=Mild redness, 3=Moderate redness, 4=Severe redness)
| Percentage of Participants | Carboxymethylcellulose and Glycerin | Sodium Hyaluronate |
|---|---|---|
| Week 1 - Clear/White | 5.0 | 3.8 |
| Week 1 - Slight | 75.0 | 59.6 |
| Week 1 - Mild | 17.5 | 36.5 |
| Week 1 - Moderate | 2.5 | 0.0 |
| Week 1 - Severe | 0.0 | 0.0 |
| Month 1 - Clear/White | 0.0 | 0.0 |
| Month 1 - Slight | 71.4 | 71.2 |
| Month 1 - Mild | 28.6 | 28.8 |
| Month 1 - Moderate | 0.0 | 0.0 |
| Month 1 - Severe | 0.0 | 0.0 |
Mean comfort judged on a 100 point visual analogue scale (0=Very Poor, 100=Excellent)
| Units on a scale | Carboxymethylcellulose and Glycerin | Sodium Hyaluronate |
|---|---|---|
| Ocular Comfort - Waking (Wk.1) | 67.05 ± 24.90 | 58.81 ± 24.73 |
| Ocular Comfort - Daytime (Wk.1) | 63.20 ± 22.05 | 68.21 ± 19.48 |
| Ocular Comfort - Evening (Wk.1) | 57.15 ± 26.30 | 63.38 ± 23.71 |
| Ocular Comfort - Waking (Mo.1) | 65.05 ± 23.48 | 63.56 ± 28.79 |
| Ocular Comfort - Daytime (Mo.1) | 68.57 ± 17.25 | 70.48 ± 23.21 |
| Ocular Comfort - Evening (Mo.1) | 60.38 ± 23.29 | 65.06 ± 23.44 |
Average daily eyedrop use
| drops/day | Carboxymethylcellulose and Glycerin | Sodium Hyaluronate |
|---|---|---|
| Daily Eyedrop Usage | 3.7 ± 1.4 | 3.3 ± 1.0 |
Lipid layer thickness as determined by lipid layer mixing pattern. A high mixing pattern = thick lipid layer.
| Lipid Layer Mixing Pattern | Carboxymethylcellulose and Glycerin | Sodium Hyaluronate |
|---|---|---|
| Week 1 | 4.50 (0 to 12) | 5.50 (1 to 10) |
| Month 1 | 3.00 (1 to 10) | 5.00 (1 to 12) |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carboxymethylcellulose and Glycerin | — | 0/21 (0%) | 2/21 (9.5%) |
| Sodium Hyaluronate | — | 0/26 (0%) | 2/26 (7.7%) |
| Event | Carboxymethylcellulose and Glycerin | Sodium Hyaluronate |
|---|---|---|
| Mild Corneal ToxicityEye disorders | 1/21 | 1/26 |
| Foot InjuryInjury, poisoning and procedural complications | 1/21 | 0/26 |
| Upper Lid CystEye disorders | 0/21 | 1/26 |
| Age Continuous(years) | Carboxymethylcellulose and Glycerin | Sodium Hyaluronate | Total |
|---|---|---|---|
| Mean | 44.8 ± 16.4 | 39.9 ± 14.8 | 42.0 ± 16.0 |
| Sex: Female, Male(Participants) | Carboxymethylcellulose and Glycerin | Sodium Hyaluronate | Total |
|---|---|---|---|
| Female | 16 | 20 | 36 |
| Male | 5 | 6 | 11 |
The record gives a start of Aug 2007, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronic Acid